<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902966</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0113</org_study_id>
    <secondary_id>NCI-2013-02078</secondary_id>
    <secondary_id>G-12-300</secondary_id>
    <nct_id>NCT01902966</nct_id>
  </id_info>
  <brief_title>Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)</brief_title>
  <official_title>Effect of a Beta Adrenergic Blockade Combined With Relaxation/Guided Imagery Audio Intervention on Symptom Distress in Women With Advanced, Recurrent Incurable Cervical Cancer - Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn how many patients with advanced,&#xD;
      recurrent, incurable cervical cancer will complete questionnaires about symptoms, any&#xD;
      anxiety, depression, and/or pain, and the quality of their lives. Researchers also want to&#xD;
      learn how many of these patients will complete a study treatment of propranolol hydrochloride&#xD;
      and relaxation and guided imagery sessions.&#xD;
&#xD;
      Researchers also want to learn if and how propranolol hydrochloride and relaxation and guided&#xD;
      imagery may affect cancer symptoms and any anxiety, depression, and/or pain, and quality of&#xD;
      life.&#xD;
&#xD;
      Propranolol hydrochloride is designed to block certain chemicals that affect the heart.&#xD;
&#xD;
      Relaxation and guided imagery sessions are a form of relaxing meditation that involves&#xD;
      tensing and relaxing various parts of your body from your feet to your head. In the guided&#xD;
      imagery portion, you listen to recordings that are designed to help with calmness, control,&#xD;
      and decreasing stress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Therapy Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will take propranolol by&#xD;
      mouth 2 times a day.&#xD;
&#xD;
      While taking the drug, you should continue to check your blood pressure daily with your own&#xD;
      personal blood pressure machine, at your local pharmacy, or in the clinic. If you are&#xD;
      personally monitoring your blood pressure, you should contact the research nurse if the&#xD;
      systolic blood pressure (SBP - the higher number) is less than 110, or if the diastolic (DBP&#xD;
      - the lower number) is less than 50 (or your heart rate is 50-60 and you show symptoms at 2&#xD;
      different timepoints 24 hours apart). The study doctor may decide to lower or raise your dose&#xD;
      of study drug during the study based on your heart rate and/or blood pressure measurements.&#xD;
&#xD;
      You will fill out a pill diary to write down the doses of propranolol that you take each day.&#xD;
&#xD;
      For the relaxation and guided imagery sessions, you will be given an MP3 player with an audio&#xD;
      recording that you should listen to 2 times a week for up to 4 months (or longer if you&#xD;
      choose). The study staff will talk to you about how to complete the sessions. You will fill&#xD;
      out a relaxation diary to write down whether you were able to complete the sessions and&#xD;
      whether you had any difficulties with it, such as distractions.&#xD;
&#xD;
      You should bring both diaries to the clinic at each visit.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At Month 1:&#xD;
&#xD;
        -  Your vital signs will be measured.&#xD;
&#xD;
        -  You will be asked about any side effects you may have had.&#xD;
&#xD;
      At Months 2 and 4:&#xD;
&#xD;
        -  Your vital signs will be measured.&#xD;
&#xD;
        -  You will be asked about any side effects you may have had. Blood (about 5-6 teaspoons)&#xD;
           will be drawn for routine tests and for testing on cytokines, RNA, and tumor markers.&#xD;
&#xD;
        -  You will complete the same questionnaires as at screening.&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have an EKG to check your heart function.&#xD;
&#xD;
        -  If you are an MD Anderson participant, the test to find out how many calories you need&#xD;
           to have on a daily basis will be repeated.&#xD;
&#xD;
        -  At Month 2 only, if the doctor thinks it is needed, you will have a CT scan of the&#xD;
           chest, abdomen, and pelvis to check the status of the disease.&#xD;
&#xD;
        -  At Month 4 only, any updates to your medical history will be recorded. You will have a&#xD;
           physical exam.&#xD;
&#xD;
      Length of Treatment:&#xD;
&#xD;
      You may continue the study therapy for as long as the doctor thinks it is in your best&#xD;
      interest. You will no longer be able to take the study therapy if the disease gets worse, if&#xD;
      intolerable side effects occur, or if you are unable to follow study directions.&#xD;
&#xD;
      Your active participation on the study will be over after the last visit. The study staff&#xD;
      will continue checking your medical record from then on to see how you are doing.&#xD;
&#xD;
      This is an investigational study. Propranolol is FDA approved and commercially available to&#xD;
      treat certain heart and blood pressure problems, anxiety, migraines, and tremors. Its use in&#xD;
      this study is investigational.&#xD;
&#xD;
      Up to 20 participants will be enrolled in this multicenter study. Up to 5 will be enrolled at&#xD;
      the Harris Health System. Up to 10 will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual and lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">September 11, 2013</start_date>
  <completion_date type="Actual">August 14, 2020</completion_date>
  <primary_completion_date type="Actual">August 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Completing Symptom Inventories</measure>
    <time_frame>2 months</time_frame>
    <description>To determine the proportion of patients completing symptom inventory, anxiety and depression survey, pain inventory, and quality of life surveys (MDASI, HADS&lt; BPI, FACT-Cx).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Propranolol + Relaxation/Guided Imagery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).</description>
    <arm_group_label>Propranolol + Relaxation/Guided Imagery</arm_group_label>
    <other_name>Betachron</other_name>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diary</intervention_name>
    <description>Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.</description>
    <arm_group_label>Propranolol + Relaxation/Guided Imagery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relaxation Audio Recording</intervention_name>
    <description>Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.</description>
    <arm_group_label>Propranolol + Relaxation/Guided Imagery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires completed at baseline, 2 months, and 4 months.</description>
    <arm_group_label>Propranolol + Relaxation/Guided Imagery</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Proven recurrent cervical cancer of any histology not eligible for curative&#xD;
             radiotherapy or surgery.&#xD;
&#xD;
          2. Failed chemotherapy for first recurrence (excluding chemotherapy with concurrent&#xD;
             irradiation) or refractory to first line systemic therapy.&#xD;
&#xD;
          3. Measurable or non-measurable disease&#xD;
&#xD;
          4. Unlimited prior therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients whose disease may be cured by surgery or radiotherapy.&#xD;
&#xD;
          2. Contraindication to use of a beta-blocker.(uncontrolled DM, COPD-unstable, Bradycardia&#xD;
             &lt;50 BPM)&#xD;
&#xD;
          3. Already receiving a beta-blocker.&#xD;
&#xD;
          4. Performance status &gt;3. Must have had treatment for first line recurrence&#xD;
&#xD;
          5. Prior radiation therapy for localized cancer of the breast, head and neck, or skin is&#xD;
             permitted provided that it was completed more than 3 years prior to registration, and&#xD;
             the patient remains free of recurrent or metastatic disease.&#xD;
&#xD;
          6. With the exception of non-melanoma skin cancer and other specific malignancies as&#xD;
             noted above, patients with other invasive malignancies who had (or have) any evidence&#xD;
             of the other cancer present within the last five years or whose previous cancer&#xD;
             treatment contraindicates this protocol therapy are excluded.&#xD;
&#xD;
          7. Use of systemic glucocorticoids such as Prednisone or Decadron in the last month for&#xD;
             greater than one week&#xD;
&#xD;
          8. Inability to accurately answer questions (e.g. dementia, brain metastases) or speak&#xD;
             English or Spanish.&#xD;
&#xD;
          9. Cirrhosis of the liver&#xD;
&#xD;
         10. Patients under the age of 18&#xD;
&#xD;
         11. History of comorbid conditions: Addison's disease, autoimmune hepatitis, hepatitis B,&#xD;
             hepatitis C, AIDS or HIV, lupus erythematosus, mixed connective tissue disease,&#xD;
             rheumatoid arthritis.&#xD;
&#xD;
         12. Hypersensitivity to propranolol, or beta-blockers&#xD;
&#xD;
         13. Uncompensated congestive heart failure&#xD;
&#xD;
         14. Cardiogenic shock&#xD;
&#xD;
         15. Severe sinus bradycardia; heart block, second or third degree or sick sinus syndrome&#xD;
             (if no artificial pacemaker present)&#xD;
&#xD;
         16. Severe hyperactive airway disease (chronic obstructive pulmonary disease, asthma)&#xD;
&#xD;
         17. Any patients on Avastin or any other anti-angiogenic drugs.&#xD;
&#xD;
         18. Patients with brittle diabetes mellitus (DM). Brittle diabetes mellitus is a type of&#xD;
             diabetes when a person's blood glucose (sugar) level often swings quickly from high to&#xD;
             low and from low to high. Also called &quot;unstable diabetes&quot; or &quot;labile diabetes.&quot;&#xD;
&#xD;
         19. Patients participating in or who plan to participate in other treatment trials during&#xD;
             the course of this study.&#xD;
&#xD;
         20. Patients actively using cocaine&#xD;
&#xD;
         21. Cannot be receiving any other active neoplastic treatment during 4 months of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lois M. Ramondetta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lyndon B. Johnson General Hospital (LBJ)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <results_first_submitted>July 8, 2021</results_first_submitted>
  <results_first_submitted_qc>September 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>Propranolol</keyword>
  <keyword>Betachron</keyword>
  <keyword>Inderal</keyword>
  <keyword>Beta blocker</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <keyword>Symptom inventory</keyword>
  <keyword>Anxiety and depression survey</keyword>
  <keyword>Pain inventory</keyword>
  <keyword>Quality of life survey</keyword>
  <keyword>Relaxation audio recording</keyword>
  <keyword>MP3 player</keyword>
  <keyword>Diary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT01902966/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 09/2013 until 02/2015. All the recruitment was done in a medical clinic setting.</recruitment_details>
      <pre_assignment_details>6 patients were registered on this study but only 5 received treatment - 1 patient signed consent but did not receive any treatment on study due to physician decision after consultation with cardiology</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Propranolol + Relaxation/Guided Imagery</title>
          <description>A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All registered participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Propranolol + Relaxation/Guided Imagery</title>
          <description>A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="31" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Completing Symptom Inventories</title>
        <description>To determine the proportion of patients completing symptom inventory, anxiety and depression survey, pain inventory, and quality of life surveys (MDASI, HADS&lt; BPI, FACT-Cx).</description>
        <time_frame>2 months</time_frame>
        <population>data were not collected due to protocol terminated early.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol + Relaxation/Guided Imagery</title>
            <description>A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Completing Symptom Inventories</title>
          <description>To determine the proportion of patients completing symptom inventory, anxiety and depression survey, pain inventory, and quality of life surveys (MDASI, HADS&lt; BPI, FACT-Cx).</description>
          <population>data were not collected due to protocol terminated early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline, 2 months and 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Propranolol + Relaxation/Guided Imagery</title>
          <description>A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine Output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>BUN increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to early termination, low accrual and lack of funding unable to determine the primary outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lois M. Ramondetta, MD, Professor, Gynecologic Oncology &amp; Reproductive Medicine</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-0307</phone>
      <email>lramonde@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

